Experimental vaccine displays potential in type 1 diabetes

06/27/2013 | Reuters

Insulin-treated type 1 diabetes patients who received the experimental vaccine TOL-3021 once weekly showed increased C-peptide levels and attained reductions in T-cell rates, according to a study in Science Translational Medicine. The vaccine also helped preserve some remaining beta cells in patients at 12 weeks without side effects, researchers noted.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Corporate Counsel - Healthcare Law Group
Genentech
South San Francisco, CA
Manager/Senior Manager, Health Services Analytics
Avalere Health
Washington, DC